2 results
Approved WMOCompleted
Primary Objective:To demonstrate that CHF 1535 twice daily is superior to Formoterol twice daily in terms of COPD exacerbations rate during 48 weeks of treatment and in terms of pulmonary function (change in pre-dose morning FEV1 from baseline to 12…
Approved WMOSuspended
The aim of this study is to identify whether it is possible to safely discontinue treatment in stable RRMS patients who have shown no evidence of active inflammation in the years prior to inclusion in terms of the return of inflammatory disease…